Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
October 20 2020 - 6:00AM
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,
USA: RVVTF), a specialty life sciences company focused on the
research and development of therapeutics for medical needs and rare
disorders, is pleased to announce it has signed a supply agreement
(the “Agreement”) with Havn Life Sciences Inc. (CSE : HAVN) (FRA:
5NP) (“Havn Life”) to source naturally-derived psychedelic
compounds, such as psilocybin, for use in future investigational
new drug (“IND”) enabling studies and clinical trials under the
Food and Drug Administration (“FDA”) guidelines.
"We are excited about our strategic partnership
with Havn Life as one of our suppliers of psychoactive compounds
that we intend to develop and commercialize using our established
tannin-chitosan based proprietary oral-thin film delivery system,
for the pharmaceutical and wellness markets,” said Michael Frank,
Revive’s Chief Executive Officer. “We are developing unique
products with both synthetic and naturally-derived psilocybin and
building relationships with companies and institutions that support
our objectives in the psychedelic space including our established
relationship with the University of Wisconsin-Madison in the
research and clinical development of our novel Psilocybin oral-thin
film product and the Phase 1 clinical study using psilocybin in the
treatment of methamphetamine use disorder.”
Havn Life Sciences is focused on standardized,
quality-controlled extraction of psychoactive compounds from plants
and fungi, and the development of natural health care products from
non-regulated compounds.
Susan Chapelle, Co-CEO, Havn Life added: “Our
path at Havn Life has always been very clear: to supply
standardized, quality controlled compounds to researchers so they
can do the research that’s necessary to document health and
wellness benefits of psychedelic medicine and ultimately help the
industry with the knowledge required to legalize these compounds.
We are thrilled to have signed this supply agreement with Revive
Therapeutics to help further their work in this field. Both of our
companies are leading innovators in the space, and we look forward
to helping Revive achieve their goals with our compound
supply.”
Revive’s Psilocybin Oral Thin-film Product
Under its sponsored research partnership with
the Reed Research Group out of the University of Wisconsin-Madison,
the Company is developing its tannin-chitosan composite of orally
dissolvable thin films which offers a unique delivery platform for
therapeutic doses (1-20mg) of psilocybin into the oral cavity.
There are a number of advantages and benefits of an orally
dissolvable psilocybin thin film such as the rapid dissolving and
onset of action to the bloodstream, the ease and convenience for
patients to administer without the need of water, chewing or
swallowing, the potential of improved therapeutic outcomes and
efficacy for underserved diseases and disorders including the
flexibility to create accurate dosing and tasteful options. The
Company’s delivery technology is a natural, non-toxic,
biodegradable and biocompatible composite that combines a tannin
material, which is derived from a plant group having antibacterial,
antifungal, antioxidant and wound healing properties, and a
chitosan material, which is derived from the crustacean group
having blood-clotting and antimicrobial properties. The delivery
technology has a rapid onset of action and controlled or sustained
release potential capabilities and may allow combining multiple
extracts from mushrooms in one formulation.
Revive’s Clinical Study of Psilocybin in the
Treatment of Methamphetamine Use Disorder
The Company has entered into a Clinical Trial
Agreement with the Board of Regents of the University of Wisconsin
System to conduct a clinical study entitled “Phase I Study of the
Safety and Feasibility of Psilocybin in Adults with Methamphetamine
Use Disorder.” The Phase I study Principal Investigator is Dr.
Christopher R. Nicholas, Ph.D., Assistant Professor of Program for
Research Outreach Therapeutics and Education in the Addictions in
the Department of Family Medicine and Community Health at
University of Wisconsin School of Medicine and Public Health. The
clinical study will be conducted at the University of
Wisconsin-Madison, School of Medicine and Public Health, and School
of Pharmacy, which holds a Wisconsin special authorization and DEA
license to perform clinical research with psilocybin. The Company
will have exclusive access to key intellectual property from this
study.
About Revive Therapeutics
Ltd.
Revive is a life sciences company focused on the
research and development of therapeutics for infectious diseases
and rare disorders, and it is prioritizing drug development efforts
to take advantage of several regulatory incentives awarded by the
FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare
Pediatric Disease designations. Currently, the Company is exploring
the use of Bucillamine for the potential treatment of infectious
diseases, with an initial focus on severe influenza and COVID-19.
With its recent acquisition of Psilocin Pharma Corp., Revive is
advancing the development of Psilocybin-based therapeutics in
various diseases and disorders. Revive’s cannabinoid pharmaceutical
portfolio focuses on rare inflammatory diseases and the company was
granted FDA orphan drug status designation for the use of
Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and
to treat ischemia and reperfusion injury from organ
transplantation. For more information, visit
www.ReviveThera.com.
For more information, please contact:
Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel:
1 888 901 0036Email:
mfrank@revivethera.comWebsite:
www.revivethera.comNeither the Canadian Securities
Exchange nor its Regulation Services Provider have reviewed or
accept responsibility for the adequacy or accuracy of this
release.
Cautionary Statement
This press release contains ‘forward-looking
information’ within the meaning of applicable Canadian securities
legislation. These statements relate to future events or future
performance. The use of any of the words “could”, “intend”,
“expect”, “believe”, “will”, “projected”, “estimated” and similar
expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking
information and are based on Revive’s current belief or assumptions
as to the outcome and timing of such future events. Forward looking
information in this press release includes information with respect
to the Offering, including the intended use of proceeds.
Forward-looking information is based on reasonable assumptions that
have been made by Revive at the date of the information and is
subject to known and unknown risks, uncertainties, and other
factors that may cause actual results or events to differ
materially from those anticipated in the forward-looking
information. Given these risks, uncertainties and assumptions, you
should not unduly rely on these forward-looking statements. The
forward-looking information contained in this press release is made
as of the date hereof, and Revive is not obligated to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. The foregoing statements expressly
qualify any forward-looking information contained herein. Reference
is made to the risk factors disclosed under the heading “Risk
Factors” in the Company’s annual MD&A for the fiscal year ended
June 30, 2019, which has been filed on SEDAR and is available under
the Company’s profile at www.sedar.com.
Revive Therapeutics (CSE:RVV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Revive Therapeutics (CSE:RVV)
Historical Stock Chart
From Oct 2023 to Oct 2024